Double attack on devastating skin cancer
NCT ID NCT04930653
Summary
This study is testing a two-part treatment for a severe, widespread red rash caused by a rare skin cancer called cutaneous T-cell lymphoma (CTCL). It combines a drug (mogamulizumab) that targets cancer cells with a blood treatment (ECP) that aims to boost the immune system. The goal is to see if this combination can effectively control the disease and is safe for patients who haven't had the drug before.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEZARY SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute of Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.